SCHEMBL2376616

SCHEMBL2376616

CN(C)CCc1cccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.54
ADRA2A P08913 3/20 0.51
ADRA2B P18089 3/20 0.51
CYP1A2 P05177 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM5 P08912 1/20 0.51
CYP2D6 P10635 1/20 0.51
CHRM1 P11229 1/20 0.51
CYP2C9 P11712 1/20 0.51
NFKB1 P19838 1/20 0.51
DRD1 P21728 1/20 0.51
SLC6A2 P23975 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
SLC6A4 P31645 1/20 0.51
HRH1 P35367 1/20 0.51
OPRM1 P35372 1/20 0.51
HTR2B P41595 1/20 0.51
HTR6 P50406 1/20 0.51
SLC6A3 Q01959 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4599895 0.98 KDM4E (0.53) TAAR1ADRA2AADRA2BCYP1A2CHRM2
SCHEMBL2376358 0.88 TAAR1 (0.55) TAAR1ADRA2AADRA2BCYP1A2CHRM2
Hydrochloric Acid SCHEMBL9471912 0.86 TAAR1 (0.53) TAAR1ADRA2AADRA2BCYP1A2CHRM2
SCHEMBL9799324 0.86 TAAR1 (0.53) TAAR1ADRA2AADRA2BCYP1A2CHRM2
SCHEMBL1304013 0.82
SCHEMBL10937071 0.82 DRD2 (0.49) TAAR1ADRA2AADRA2BCYP1A2CHRM2
SCHEMBL21034335 0.80 DRD2 (0.55) TAAR1ADRA2AADRA2BCHRM1DRD1
Hydrochloric Acid SCHEMBL28582399 0.80 HPGD (0.53) TAAR1ADRA2AADRA2BCYP1A2CHRM2
SCHEMBL1780110 0.79 DRD2 (0.58) TAAR1ADRA2AADRA2BCYP1A2CHRM2
Hydrochloric Acid SCHEMBL11064048 0.79 TAAR1 (0.46) TAAR1ADRA2AADRA2BCYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127728-A1 Constrained Ionizable Cationic Lipids and Lipid Nanoparticles CAPSTAN THERAPEUTICS, INC. 2025-04-24 US disclosed
CN-110054865-B Resin composition 味之素株式会社 2024-05-14 CN disclosed
CN-117957068-A Method for discharging resin composition, method for manufacturing electronic component, and electronic component 纳美仕有限公司 2024-04-30 CN disclosed
CN-117957270-A Resin composition for injection dispensing, adhesive for electronic component, cured product thereof, and electronic component 纳美仕有限公司 2024-04-30 CN disclosed
CN-117940488-A Resin composition, adhesive for electronic component, cured product thereof, and electronic component 纳美仕有限公司 2024-04-26 CN disclosed
EP-2963076-B9 HYDROPHILIC BLOCK COPOLYMERS AND MEMBRANES PREPARED THEREFROM PALL CORP (US) 2023-12-06 EP disclosed
CN-114636768-B Detection method for thiamethoxam residues in jasmine flowers 广西-东盟食品检验检测中心 2023-11-07 CN disclosed
EP-2963076-B1 HYDROPHILIC BLOCK COPOLYMERS AND MEMBRANES PREPARED THEREFROM PALL CORP (US) 2023-09-13 EP disclosed
CN-116715939-A Curable resin composition, adhesive, and adhesive method 味之素株式会社 2023-09-08 CN disclosed
CN-116063978-A Curable composition 味之素株式会社 2023-05-05 CN disclosed
WO-1999034839-A1 METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1999034914-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1999034915-A1 FLOW DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1998030327-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS CERUS CORPORATION (US) 1998-07-16 WO disclosed
EP-0226896-B1 LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF Takeda Chemical Industries, Ltd. (JP) 1993-09-15 EP disclosed
EP-0362137-A2 Molded polymers with hydrophilic surfaces, and process for making them CIBA-GEIGY AG (CH) 1990-04-04 EP disclosed
US-4914206-A ANTIBIOTICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-04-03 US disclosed
EP-0289262-A2 Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1988-11-02 EP disclosed
EP-0226896-A2 Lankacidin derivatives and production thereof Takeda Chemical Industries, Ltd. (JP) 1987-07-01 EP disclosed
US-4506007-A TREATED WITH N,N'-DISUBSTITUTED-S-(DIMETHYLAMINO) ETHYTL)-ISOTHIOUREAS FUJI PHOTO FILM CO., LTD. (JP) 1985-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127728-A1 Constrained Ionizable Cationic Lipids and Lipid Nanoparticles LNPEP, PLTP, SARNP TAAR1 2735/4885ADRA2A 4762/4885ADRA2B 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.